Skip to main content
. 2018 Apr 17;23(8):887–e94. doi: 10.1634/theoncologist.2018-0100

Figure 1.

image

Kaplan‐Meier plot. Overall survival (OS) and PFS comparing cohort 1, 30 mg by mouth (PO) weekly (n = 24), with cohort 2, 10 mg PO daily (n = 9). Median OS was 12.2 months versus 8.1 months, respectively; no PFS advantage was seen in either group (2.1 months vs. 1.8 months).

Abbreviation: PFS, progression‐free survival.